New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)

Project Information

PAH-HOPE

Grant agreement ID: 822258

DOI 10.3030/822258

Project closed

EC signature date 17 July 2018

Start date 1 October 2018

End date 31 March 2021

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 3 570 000,00

EU contribution € 2 499 000,00

Coordinated by

ATXA THERAPEUTICS LTD
Ireland

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Open Research Data Pilot (1)

KOL Engagement, Communication & Dissemination

Engagement, communication & dissemination of recent development and progress on ATXA’s lead drug NTP42 including with key opinion leaders (KOLs) and other stakeholders of relevance to pulmonary arterial hypertension (PAH).

Publications

Peer reviewed articles (3)

Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Author(s): Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Pedro Mendes-Ferreira, Rui Adão, Carmen Brás-Silva, B. Therese Kinsella
Published in: European Journal of Pharmacology, Issue 889, 2020, Page(s) 173658, ISSN 0014-2999
Publisher: Elsevier BV
DOI: 10.1016/j.ejphar.2020.173658

Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation

Author(s): Eamon P. Mulvaney, Áine G. O'Sullivan, Sarah B. Eivers, Helen M. Reid, B. Therese Kinsella
Published in: Experimental and Molecular Pathology, Issue 110, 2019, Page(s) 104277, ISSN 0014-4800
Publisher: Academic Press
DOI: 10.1016/j.yexmp.2019.104277

NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Author(s): Eamon P. Mulvaney, Helen M. Reid, Lucia Bialesova, Annie Bouchard, Dany Salvail, B. Therese Kinsella
Published in: BMC Pulmonary Medicine, Issue 20/1, 2020, ISSN 1471-2466
Publisher: BioMed Central
DOI: 10.1186/s12890-020-1113-2

Conference proceedings (2)

NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension

Author(s): T Kinsella, E Mulvaney, HM Reid
Published in: European Respiratory Journal, 2019, Page(s) PA5048
Publisher: European Respiratory Society

Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension

Author(s): T Kinsella, E Mulvaney, HM Reid
Published in: European Journal of Cardiology, Issue 40, 2019, Page(s) P3670
Publisher: Oxford Academic

Intellectual Property Rights

Patent (1)

THROMBOXANE RECEPTOR ANTAGONISTS

Application/Publication number: 16 739541
Date: 2016-06-13
Applicant(s): ATXA THERAPEUTICS LTD